[go: up one dir, main page]

CA2371279A1 - Vaccin de recombinaison contre la neurotoxine botulique - Google Patents

Vaccin de recombinaison contre la neurotoxine botulique Download PDF

Info

Publication number
CA2371279A1
CA2371279A1 CA002371279A CA2371279A CA2371279A1 CA 2371279 A1 CA2371279 A1 CA 2371279A1 CA 002371279 A CA002371279 A CA 002371279A CA 2371279 A CA2371279 A CA 2371279A CA 2371279 A1 CA2371279 A1 CA 2371279A1
Authority
CA
Canada
Prior art keywords
serotype
bont
nucleic acid
seq
bont serotype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002371279A
Other languages
English (en)
Inventor
Leonard A. Smith
Michael P. Byrne
John L. Middlebrook
Hugh Lapenotiere
Michael A. Clayton
Douglas R. Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Army Medical Research and Development Command
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2371279A1 publication Critical patent/CA2371279A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne la préparation et l'expression de gènes de synthèse codant des polypeptides contenant des épitopes protecteurs de neurotoxine botulique (BoNT). L'invention porte également sur la production de peptides immunogènes codés par ces gènes de synthèse, de même que la récupération et la purification de peptides immunogènes à partir d'organismes de recombinaison. L'invention concerne enfin des procédés de vaccination contre la neurotoxine botulique utilisant les peptides exprimés.
CA002371279A 1999-05-12 2000-05-12 Vaccin de recombinaison contre la neurotoxine botulique Abandoned CA2371279A1 (fr)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US13387399P 1999-05-12 1999-05-12
US13386799P 1999-05-12 1999-05-12
US13386599P 1999-05-12 1999-05-12
US13386899P 1999-05-12 1999-05-12
US13386699P 1999-05-12 1999-05-12
US13386999P 1999-05-12 1999-05-12
US60/133,868 1999-05-12
US60/133,866 1999-05-12
US60/133,867 1999-05-12
US60/133,869 1999-05-12
US60/133,865 1999-05-12
US60/133,873 1999-05-12
US14619299P 1999-07-29 1999-07-29
US60/146,192 1999-07-29
PCT/US2000/012890 WO2000067700A2 (fr) 1999-05-12 2000-05-12 Vaccin de recombinaison contre la neurotoxine botulique

Publications (1)

Publication Number Publication Date
CA2371279A1 true CA2371279A1 (fr) 2000-11-16

Family

ID=27568892

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002371279A Abandoned CA2371279A1 (fr) 1999-05-12 2000-05-12 Vaccin de recombinaison contre la neurotoxine botulique

Country Status (5)

Country Link
EP (1) EP1180999A4 (fr)
JP (1) JP2004512004A (fr)
AU (1) AU783450B2 (fr)
CA (1) CA2371279A1 (fr)
WO (1) WO2000067700A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7227010B2 (en) * 1993-09-21 2007-06-05 United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US7037680B2 (en) * 1993-09-21 2006-05-02 The United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
WO2003012117A1 (fr) * 2001-07-28 2003-02-13 The Secretary Of State For Defence Vaccin a adn
US7825233B2 (en) 2004-06-30 2010-11-02 Allergan, Inc. Optimizing expression of active Botulinum Toxin type E
CA2575994A1 (fr) * 2004-08-04 2006-02-16 Allergan, Inc. Optimisation de l'expression de toxine botulinique active de type a
FR2889066B1 (fr) * 2005-07-28 2007-11-09 Centre Nat Rech Scient Procede d'immunisation genetique par electrotransfert contre une toxine et antiserum susceptible d'etre obtenu par ledit procede
JP2009106163A (ja) * 2007-10-26 2009-05-21 Kyushu Univ 核酸配列、ベクター、形質転換体、製造方法、及び、核酸配列プライマー
RU2545825C9 (ru) 2009-10-21 2015-06-20 Мерц Фарма Гмбх Унд Ко. Кгаа Система для определения непроцессированного и частично процессированного нейротоксина типа а
GB201312317D0 (en) * 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
JP6601922B2 (ja) * 2015-01-09 2019-11-06 イプセン バイオイノベーション リミテッド 陽イオン性神経毒
KR20180021703A (ko) * 2015-05-15 2018-03-05 보드 오브 리젠츠 오브 디 유니버시티 오브 네브라스카 선택된 세포로 분자를 전달하도록 개조된 조작된 클로스트리디움 보툴리눔 독소
SG11202005757SA (en) * 2017-12-20 2020-07-29 Allergan Inc Botulinum toxin cell binding domain polypeptides and methods of use for skin rejuvenation
CN110075288B (zh) * 2019-05-06 2022-04-26 中国兽医药品监察所 一种无毒c型肉毒梭菌基因工程亚单位疫苗及其生产方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9511909D0 (en) * 1995-06-12 1995-08-09 Microbiological Res Authority Vaccine

Also Published As

Publication number Publication date
AU5003500A (en) 2000-11-21
WO2000067700A3 (fr) 2001-02-08
WO2000067700A2 (fr) 2000-11-16
EP1180999A4 (fr) 2005-03-30
JP2004512004A (ja) 2004-04-22
EP1180999A2 (fr) 2002-02-27
AU783450B2 (en) 2005-10-27

Similar Documents

Publication Publication Date Title
US7786285B2 (en) Recombinant vaccine against botulinum neurotoxin
Byrne et al. Development of vaccines for prevention of botulism
Byrne et al. Fermentation, purification, and efficacy of a recombinant vaccine candidate against botulinum neurotoxin type F from Pichia pastoris
US8012479B2 (en) Recombinant toxin fragments
DK2248822T3 (en) MENINGOCOKKER ADHESIONS
EP1824971B1 (fr) Genes clostridiaux genetiquement modifies, proteines codees par ces genes modifies et utilisations de ceux-ci
Webb et al. Protection with recombinant Clostridium botulinum C1 and D binding domain subunit (Hc) vaccines against C and D neurotoxins
AU783450B2 (en) Recombinant vaccine against botulinum neurotoxin
US20130345398A1 (en) Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US8372405B2 (en) Proteins with improved solubility and methods for producing and using same
US7037680B2 (en) Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US7227010B2 (en) Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
EP0500736B1 (fr) Vaccin recombine contre la pleuropneumonie porcine
US6287566B1 (en) Protective peptides neurotoxin of C. botulinum
AU2002228887A1 (en) Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US8153397B2 (en) Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US20030185850A1 (en) Protective peptides neurotoxin of C. botulinum
US20060141572A1 (en) Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
WO2005034841A2 (fr) Vaccin contre l'anthrax
CN118852463A (zh) 一种交联蛋白vaccine-EBA1及其制备方法和应用
CA2078801A1 (fr) Phospholipase d enzymatiquement inactive de corynebacterium pseudotuberculosis

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued